The 7 major peanut allergy markets reached a value of US$ 445.4 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 939.2 Million by 2034, exhibiting a growth rate (CAGR) of 8.64% during 2023-2034.
The peanut allergy market has been comprehensively analyzed in this report titled "Peanut Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Peanut allergy, also known as peanut hypersensitivity, is a food allergy in which the immune system mistakenly identifies peanut proteins as harmful and triggers an allergic reaction. This response occurs within minutes following direct or indirect contact with peanuts. Symptoms of the ailment can range from mild, such as itching and hives, to severe, including anaphylaxis, a life-threatening reaction that can cause difficulty breathing, swelling of the throat, and a drop in blood pressure. Individuals suffering from this illness may also experience digestive problems like stomach cramps, indigestion, diarrhea, nausea, vomiting, etc. The diagnosis of peanut allergy typically involves a combination of physical examination and underlying indications. Additionally, the doctor may investigate the patient's medical history, including a family history of allergies or any known allergies. A blood workup is utilized to monitor the antibodies in the bloodstream against allergies. The healthcare provider may perform certain assessment studies, such as skin prick tests and oral food challenges, to confirm a diagnosis in the patients.
The rising incidences of allergic reactions resulting from an overactive immune system against certain substances or foods are primarily driving the peanut allergy market. In addition to this, the increasing cases of impaired skin barriers due to atopic dermatitis, leading to exposure and penetration of food allergens, are also propelling the market growth. Moreover, the widespread adoption of effective medications, such as epinephrine and antihistamines, to help manage symptoms during an allergic reaction is creating a positive outlook for the market. Apart from this, the escalating utilization of the radioallergosorbent test (RAST) to diagnose the ailment since it aids in identifying the amount of allergen-specific IgE antibodies in the blood is also bolstering the market growth. Furthermore, several key players are making substantial investments in developing novel therapies that target particular pathways to provide more effective relief of indications. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of oral immunotherapy, which is designed to offer durable desensitization to peanuts and reduce the risk of severe reactions, is expected to drive the peanut allergy market during the forecast period.
This report provides an exhaustive analysis of the peanut allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for peanut allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the peanut allergy market in any manner.
The peanut allergy market has been comprehensively analyzed in this report titled "Peanut Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Peanut allergy, also known as peanut hypersensitivity, is a food allergy in which the immune system mistakenly identifies peanut proteins as harmful and triggers an allergic reaction. This response occurs within minutes following direct or indirect contact with peanuts. Symptoms of the ailment can range from mild, such as itching and hives, to severe, including anaphylaxis, a life-threatening reaction that can cause difficulty breathing, swelling of the throat, and a drop in blood pressure. Individuals suffering from this illness may also experience digestive problems like stomach cramps, indigestion, diarrhea, nausea, vomiting, etc. The diagnosis of peanut allergy typically involves a combination of physical examination and underlying indications. Additionally, the doctor may investigate the patient's medical history, including a family history of allergies or any known allergies. A blood workup is utilized to monitor the antibodies in the bloodstream against allergies. The healthcare provider may perform certain assessment studies, such as skin prick tests and oral food challenges, to confirm a diagnosis in the patients.
The rising incidences of allergic reactions resulting from an overactive immune system against certain substances or foods are primarily driving the peanut allergy market. In addition to this, the increasing cases of impaired skin barriers due to atopic dermatitis, leading to exposure and penetration of food allergens, are also propelling the market growth. Moreover, the widespread adoption of effective medications, such as epinephrine and antihistamines, to help manage symptoms during an allergic reaction is creating a positive outlook for the market. Apart from this, the escalating utilization of the radioallergosorbent test (RAST) to diagnose the ailment since it aids in identifying the amount of allergen-specific IgE antibodies in the blood is also bolstering the market growth. Furthermore, several key players are making substantial investments in developing novel therapies that target particular pathways to provide more effective relief of indications. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of oral immunotherapy, which is designed to offer durable desensitization to peanuts and reduce the risk of severe reactions, is expected to drive the peanut allergy market during the forecast period.
This report provides an exhaustive analysis of the peanut allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for peanut allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the peanut allergy market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the peanut allergy market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the peanut allergy market
Competitive Landscape:
This report also provides a detailed analysis of the current peanut allergy marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the peanut allergy market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the peanut allergy market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the peanut allergy market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of peanut allergy across the seven major markets?
- What is the number of prevalent cases (2018-2034) of peanut allergy by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of peanut allergy by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with peanut allergy across the seven major markets?
- What is the size of the peanut allergy patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of peanut allergy?
- What will be the growth rate of patients across the seven major markets?
Peanut Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for peanut allergy drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the peanut allergy market?
- What are the key regulatory events related to the peanut allergy market?
- What is the structure of clinical trial landscape by status related to the peanut allergy market?
- What is the structure of clinical trial landscape by phase related to the peanut allergy market?
- What is the structure of clinical trial landscape by route of administration related to the peanut allergy market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Peanut Allergy - Unmet Needs10 Peanut Allergy - Key Endpoints of Treatment13. Peanut Allergy - Attribute Analysis of Key Marketed and Pipeline Drugs16 Peanut Allergy - Recent Events and Inputs From Key Opinion Leaders18 Peanut Allergy Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Peanut Allergy - Introduction
5 Peanut Allergy - Disease Overview
7 Peanut Allergy - Epidemiology and Patient Population
8 Peanut Allergy - Treatment Algorithm, Guidelines, and Medical Practices
11 Peanut Allergy - Marketed Products
12 Peanut Allergy - Pipeline Drugs
14. Peanut Allergy - Clinical Trial Landscape
15 Peanut Allergy - Market Scenario
17 Peanut Allergy Market - SWOT Analysis
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 133 |
Published | May 2024 |
Forecast Period | 2023 - 2034 |
Estimated Market Value ( USD | $ 445.4 Million |
Forecasted Market Value ( USD | $ 939.2 Million |
Compound Annual Growth Rate | 7.0% |
Regions Covered | Global |